摘要
目的分析紫杉醇联合顺铂同步放化疗在晚期食管癌患者中的应用效果。方法将100例晚期食管癌患者随机分为对照组(50例,5-FU联合顺铂同步放化疗)和观察组(50例,紫杉醇联合顺铂同步放化疗)。比较两组的临床疗效、血清肿瘤标志物水平以及不良反应。结果两组客观缓解率(70.00%vs.52.00%)比较差异无统计学意义(P>0.05);观察组疾病控制率为92.00%,高于对照组的74.00%(P<0.05)。治疗6个周期后,观察组的血清细胞角蛋白19片段(CYFRA21-1)、鳞状细胞癌抗原(SCC)水平低于对照组(P<0.05)。两组患者治疗期间的不良反应发生率(12.00%vs.14.00%)比较无统计学差异(P>0.05)。结论紫杉醇联合顺铂同步放化疗可提升对晚期食管癌的疾病控制率,下调患者血清肿瘤标志物水平,保障用药安全。
Objective To analyze the application effect of paclitaxel combined with cisplatin concurrent chemoradiotherapy in patients with advanced esophageal cancer.Methods 100 patients with advanced esophageal cancer were randomly divided into control group(50 cases,5-FU combined with cisplatin concurrent chemoradiotherapy)and observation group(50 cases,paclitaxel combined with cisplatin concurrent chemoradiotherapy).The clinical efficacy,serum tumor marker levels and adverse reactions were compared between the two groups.Results No statistical difference was found in the objective remission rate(70.00%vs.52.00%)between the two groups(P>0.05);The disease control rate of the observation group was 92.00%,higher than 74.00%of the control group(P<0.05).After 6 cycles of treatment,the serum CYFRA21-1 and SCC levels of the observation group were lower than those of the control group(P<0.05);No statistical difference was found in the incidence of adverse reactions(12.00%vs.14.00%)between the two groups during treatment(P>0.05).Conclusions Paclitaxel combined with cisplatin concurrent chemoradiotherapy can improve the disease control rate of advanced esophageal cancer,down-regulate the serum tumor marker levels,and ensure the medication safety.
作者
宁琳琳
潘雪峰
王小利
NING Linlin;PAN Xuefeng;WANG Xiooli(Department of Oncology,the 989^(th)Hospital of the Joint Logistics Support Force of the People's Liberation Army of China,Luoyang 471100,Ching)
出处
《临床医学工程》
2024年第11期1403-1404,共2页
Clinical Medicine & Engineering
关键词
晚期食管癌
紫杉醇
顺铂
同步放化疗
肿瘤标志物
Advanced esophageal cancer
Paclitaxel
Cisplatin
Concurrent chemoradiotherapy
Tumor marker
